ScholarLens Back to search
2019•Journal watchRequires access

Real-World Comparison of Dimethyl Fumarate and Teriflunomide for Relapsing Multiple Sclerosis

Robert T. Naismith

Open publisher page 0 citations

Abstract

Few head-to-head studies of multiple sclerosis (MS) treatments are available. To compare efficacy outcomes with dimethyl fumarate (DMF) versus with

About this research paper

What this paper is about

Few head-to-head studies of multiple sclerosis (MS) treatments are available. To compare efficacy outcomes with dimethyl fumarate (DMF) versus with

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Few head-to-head studies of multiple sclerosis (MS) treatments are available. To compare efficacy outcomes with dimethyl fumarate (DMF) versus with

Key concepts: Dimethyl fumarate, Teriflunomide, Multiple sclerosis, Medicine, Internal medicine, Oncology, Immunology, Fingolimod

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Real-World Comparison of Dimethyl Fumarate and Teriflunomide for Relapsing Multiple Sclerosis — Research Paper | ScholarLens